Navigation Links
Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema
Date:12/21/2011

TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor™ System for endoscopic lung volume reduction for the treatment of severe emphysema.  InterVapor is the first non-surgical, endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving implants or foreign materials in the lung.

Clinical efficacy of InterVapor has been established by the multi-center VAPOR trial which showed a reduction in lung volume as well as statistical and clinical significance in lung function improvement (FEV1) and health-related quality of life (SGRQ) at six months. 

"Our involvement with Uptake Medical and InterVapor goes back to the first usage in patients, and we are delighted to see the TGA approval," commented Professor Gregory Snell, head of lung transplant services at the Alfred Hospital in Melbourne, Australia.  "InterVapor has continued to demonstrate clinical efficacy and safety and we look forward to offering InterVapor to our patients."

VAPOR trial investigator, Dr. Peter Hopkins of Prince Charles Hospital in Brisbane, provided insights into the relevance of new treatment options for emphysema.  "Emphysema is a debilitating condition and this patient population is in need of new treatment options.  The ability to offer InterVapor to our patients represents an important step in furthering the standard of care for the treatment of severe emphysema."

"Capping the year by obtaining TGA approval in Australia is another important milestone for Uptake Medical," said R. King Nelson, President and Chief Executive Officer, Uptake Medical. "We look forward to working with our distributor partner, Aurora BioScience, as we introduce InterVapor in Australia 2012."

About Emphysema/COPD

The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise and will become the third leading cause of death by 2030. In the U.S., where nearly 5 million people are diagnosed with emphysema, it already holds this position with one person dying every 4 minutes from COPD. Debilitating and costly, nearly $50 billion was spent addressing the direct and indirect costs associated with COPD in the U.S. in 2010.

About Uptake Medical

Uptake Medical is focused on the development and commercialization of innovative, non-surgical treatments for lung diseases.  InterVapor™ is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any implants or foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. Headquartered in Tustin, Calif., Uptake Medical® received the CE mark and TGA approval to commercialize InterVapor. More information can be found at www.uptakemedical.com.

About Aurora BioScience Pty Ltd

Headquartered in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Asia Pacific healthcare markets contribute to the enhancement of their patients' quality of life. Our areas of interest include pulmonology, cancer therapies, neurology, haematology and blood products. For more information, please visit www.aurorabioscience.com.au.

Uptake Medical and InterVapor are registered trademarks and trademarks of Uptake Medical.


'/>"/>
SOURCE Uptake Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
2. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
3. Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
4. Uptake Medical Names J.C. MacRae as Chief Financial Officer
5. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
6. Uptake Medical Announces Scott Huennekens Elected to Board of Directors
7. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
8. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
9. Uptake Medical® Expands Executive Team, Announces European General Manager Lloyd Mencinger
10. Uptake Medical Receives CE Mark for InterVapor - Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema - and Announces Positive Clinical Results
11. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology:
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
Breaking Medicine News(10 mins):